Software (Web Marketplace Saas..) • BioTech • Businesses Solutions • Sales (& Marketing) • A.I. (& Big Data) • Web Security (& Privacy) • Developer tools • Online Social
Description
General Partner at CRV
Most Interested In
AI as applied to the real-world: autonomous vehicles, cyber security, demand forecasting, etc.
Also any SaaS application (B2B only)
Focused on Seed and A's only
Not Interested In
Not interested in Consumer software, FinTech, HC IT, Bio.
Not pursuing later stage deals
Jerry Yang
Investing in Software (Web Marketplace Saas..) &b...
Software (Web Marketplace Saas..) • PropTech • IT (& TMT) • Hospitality (& Events) • Media • Education • BioTech • AgroTech • Businesses Solutions • FinTech (& Financials services) • Hardware (& Manufacturing) • Energy • Retail (& E-Commerce) • Sales (& Marketing) • Cosmetics (& Fashion) • Entertainment (& Sports) • IoT (& Wearables) • CleanTech • A.I. (& Big Data) • HealthTech (& Fitness) • Blockchain (& Cryptos) • Web Security (& Privacy) • Gaming (& eSports) • Advertising • Analytics • AR/VR • Cloud Services (& Infrastructure) • Developer tools • Future Of Work • Food & Beverage • Human Resources • Impact • Insurance (& InsurTech) • Payments • Robotics • Mobile Apps • Aerospace (& Defense) • Healthcare (& Wellness) • Music • Investment Management • LegalTech • Mobile • Mobility • Online Social • Consumer • Oil & Gas (& Mining) • Industrials • Film Production (& Distribution) • Semiconductors
Description
Jerry Yang serves as Founding Partner at AME Cloud Ventures. Yang also serves as Special Partner at Neotribe Ventures. He serves as Investor of BirdEye. He also serves as an Independent Director at Workday and Advisor at Radius. He is the Founding Partner at AME Cloud Ventures. He serves as Board Observer and Senior Advisor at Didi Kuaidi. Since March 2012, he has worked with and invests in technology entrepreneurs as the founding partner of AME Cloud Ventures, his innovation investment firm. He is also a co-founder of Yahoo! Inc., where he served as a director from March 1995 to January 2012, and as Chief Executive Officer from June 2007 to January 2009. He also led Yahoo!'s investments in Yahoo Japan and Alibaba Group Holding Limited, and he is a currently a director of Alibaba Group, where he has served on the board from October 2005 to January 2012 and from September 2014 to the present. He is also a director of Lenovo, Inc. where he has served on the board since November 2014. From July 2000 to November 2012, he was a member of Cisco Systems, Inc.'s Board of Directors, and he was a director of Yahoo! Japan from January 1996 to January 2012. He also is a director of various private companies and foundations. He received a B.S. and M.S. in Electrical Engineering from Stanford University, where he served as Vice Chair of the Board of Trustees from June 2005 until September 2016. He is also an Angel Investor. He serves as Board Member at Docker
Tony Corbin
Investing in BioTech • Businesses Solutions ...
Menlo Park , San Fran..., U.S.A. - Israel - Europe: Germany, United Kingdom, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Czech Republic, Greece, Portugal, Sweden, Hungary, Austria, Switzerland, Denmark, Finland, Slovakia, Norway, Ireland, Luxembourg, Malta, Icelan
Previous Investments
• Vayyar Imaging:
$109000000 (Later stage VC)
• VDOO:
$57000000 (Later stage VC)
• Cloudleaf:
$26000000 (Later stage VC)
• Fakespot:
(Series A)
• Fakespot:
$4000000 (Series A)
• Sumatra:
$2000000 (Seed)
• MRGN:
(Pre Seed)
• MRGN:
(Pre-Seed)
• Ash Wellness:
$3000000 (Seed)
• Ash Wellness:
(Seed+)
• AppliedXL:
$4000000 (Seed)
• AssetDash:
(Pre Seed)
• Tabula:
$3000000 (Pre Seed)
• Naya:
$6000000 (Seed)
• Thorium Data:
$100000 (Pre Seed)
• OpenAxis:
$2000000 (Pre Seed)
• CACTIVATE:
(Pre Seed)
• Grin Gaming:
(Seed)
• Grin Gaming:
(Seed)
• Docket:
(Seed)
• Ask Vera:
(Seed)
• UrsaLeo:
(Seed+)
• Cactivate:
(Pre-Seed)
• Clearforce:
(Seed)
• Paragon Intel:
(Seed+)
• Intrro:
(Seed)
• Bazze:
(Pre-Seed)
• Asset Dash:
(Pre-Seed)
• Extend:
$16000000 (Series A)
• OneCell Diagnostics:
$16000000 (Series A)
• Finicast:
$13000000 (Seed)
• Very Good Ventures:
$3000000 (Series A)
• Very Good Ventures:
$3000000 (Series A)
• Prellis Biologics:
$35000000 (Series C)
• Prellis Biologics:
$15000000 (Series B)
• Biomason:
$65000000 (Series C)
• Home Delivery Service (HDS Global):
$5000000 (Series Unknown)
• Rizzle:
$17000000 (Convertible Note)
• EnTribe:
$3000000 (Seed)
• Atonarp:
$50000000 (Series D)
• Atonarp:
$2000000 (Series B)
• Atonarp:
$4000000 (Series A)
• Boom Supersonic:
$50000000 (Series C)
• Extend, Inc.:
$16000000 (Series A)
• Quartic.ai:
$2000000 (Seed)
• Globality:
$27000000 (Series B)
• Globality:
$10000000 (Series A)
• BangDB:
(Seed)
• Reaction:
$10000000 (Series A)
• Reaction:
$2000000 (Seed)
• Shipster:
(Seed)
• H2O.ai:
$9000000 (Series A)
• Trove:
$5000000 (Series A)
• FUTR Corp.:
$5000000 (Seed)
• Yellowsmith:
$850000 (Seed)
• Printi:
$1000000 (Series A)
• GoPro:
$88000000 (Series A)
Tony Corbin
Menlo Park - San Francisco Bay Area - California, U.S.A. - Israel - Europe: Germany, United Kingdom, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Czech Republic, Greece, Portugal, Sweden, Hungary, Austria, Switzerland, Denmark, Finland, Slovakia, Norway, Ireland, Luxembourg, Malta, Icelan
Riverwood Capital is a globally-focused private equity firm that invests in high-growth businesses in the technology and services industries, across a variety of verticals and geographies. Riverwood has offices in Menlo Park, CA and New York, NY and currently has more than 20 investments in North America, Latin America and Asia. The firm's current fund has $780 million of committed capital. The final fund close was in April 2011. Riverwood invests in mid-market technology and technology enabled products and services. The firm defines mid-market as approximately $100-$500 million in revenue for product companies, and approximately $25-$150 million in revenue for software and services. Riverwood occasionally invests outside these ranges. Riverwood invests on a global basis, having already invested in the U.S., Israel, Argentina, Chile, and Brazil. The firm's normal investment size ranges from $25-75 million.
Dr. Adam Goulburn served as Partner at Lux Capital. He serves as Board Member at Eikon Therapeutics, Plexium and Mahana Therapeutics. He serves as Board Member at Drone Racing League. He served as Board member at Kallyope. He is based in the firm's New York headquarters and focuses on broad investment opportunities in healthcare IT, services, mobile health, and therapeutics. He was a Board Member of Authorea, Variant Bio & 3Scan. He has worked extensively with a number of Lux portfolio companies including Kala Pharmaceuticals and Genocea Biosciences. He is also a mentor for healthcare IT incubators Blueprint Health and Healthbox. Before joining Lux, he was a Postdoctoral Fellow of Neuroscience at Weill Cornell Medical College, researching regenerative medicine in association with brain disorders including schizophrenia and Alzheimer's disease. Originally from Australia, he has dual undergraduate degrees in Commerce and Science and subsequently completed his Ph.D. at the Australian Stem Cell Centre, having been chosen as a highly selective Premier Scholar. He has published in numerous peer-reviewed scientific journals. Prior to joining Lux in 2011, he received his Ph.D. in neuroscience from Weill Cornell Medical College. He also serves as Board Member at Vesta Healthcare. He serves as Board Member at Rivet Health and rd. MD. He is a Co-Founder of Cajal Neuroscience.
Cyril Bertrand is a Partner at Xange Captial where he is responsible for core-technology investments and for the German-speaking area.
Cyril has prior venture capital experience at DVC (Munich, Germany) where is was responsible for the Telecom & Semiconductor investments, and at TeleSoft Partners (San Mateo, CA).
Prior to that, his 7-year tenure at Alcatel brought him to the position of Director in charge of creating and growing Alcatel’s first generation of 802.11 products across France, Spain and Israel in 2000.
Cyril is also a non-exec board director of Apertio (UK), MergeOptics (Germany), Panoratio (Germany), Powerlase (UK) and is an observer at BigMachines (US).
Venrock invests in technology and healthcare. Individual focus areas: Biotechnology, Diagnostics, Genomics, Healthcare IT, Medical Devices. Prefers: category kings + big risk element
Eduardo Saverin
Investing in BioTech • Businesses Solutions ...
San Francisco Bay Are..., U.S.A. - Singapore - Brazil
Previous Investments
• iVideoSmart:
$3500000 (Series A)
• Sugar.fit:
$5000000 (Series A)
• Mswipe Technologies:
$20000000 (Series Unknown)
• Mswipe Technologies:
$31000000 (Series E)
• Mswipe Technologies:
$10000000 (Series D)
• Inspace XR:
$4000000 (Seed)
• Hopscotch:
$20000000 (Series E)
• Hopscotch:
$13000000 (Series C)
• Hopscotch:
$11000000 (Series B)
• CoinDCX:
$140000000 (Series D)
• CoinDCX:
$90000000 (Series C)
• Kopi Kenangan:
$96000000 (Series C)
• Kopi Kenangan:
$210000000 (Series B)
• Yalo:
$50000000 (Series C)
• Yalo:
$15000000 (Series B)
• Antler:
$50000000 (Series Unknown)
• Perx Technologies:
$5000000 (Series B)
• Perx Technologies:
$1000000 (Series A)
• Carro:
$30000000 (Series B)
• Carro:
$60000000 (Series B)
• CXA Group:
$25000000 (Series C)
• Tech in Asia:
$7000000 (Series Unknown)
• Tech in Asia:
$4000000 (Series C)
• INTURN:
$23000000 (Series B)
• 99.co:
$8000000 (Series A)
• 99.co:
$2000000 (Seed)
• Intelligent Video Solutions:
$4000000 (Series A)
• Jumio:
$4000000 (Debt Financing)
• Jumio:
$7000000 (Series A)
• Xfers:
$3000000 (Seed)
• Silvercar:
$28000000 (Series C)
• Silvercar:
$14000000 (Series B)
• RedMart:
$27000000 (Series C)
• RedMart:
$23000000 (Series B)
• RedMart:
$5000000 (Series Unknown)
• RedMart:
(Seed)
• Eat Just:
$90000000 (Series C)
• FlightCar:
$14000000 (Series A)
• Tag (Acquired):
$1000000 (Seed)
• Nitrous:
$7000000 (Series A)
• Nitrous:
$1000000 (Seed)
• ShopSavvy:
$7000000 (Series A)
• Qwiki:
$8000000 (Series A)
• Aporta, Inc.:
(Undisclosed)
• CrowdMob:
(Seed)
Eduardo Saverin
San Francisco Bay Area - Los Angeles, U.S.A. - Singapore - Brazil
Eduardo Saverin is a Co-Founder and serves as Partner at B Capital Group. He is a Co-Founder of Facebook. He also co-founded Velos Partners, a private equity firm based in Los Angeles and serves as its Chairman. He serves on the board of Carro, Connexions Asia and Ninja Van. He also serves as Advisor at Golden Gate Ventures.
David Wieland
Investing in Software (Web Marketplace Saas..) &b...
Toronto , Austin , Ch..., Canada, U.S.A.
Previous Investments
• RIVS:
$1500000
• The Renewal Workshop:
$8640000 (Early stage VC)
• Pattern89:
$3500000 (Early stage VC)
• The Mom Project:
• Zoro Card:
$720000 (Seed Round)
• Bold (Other Services (B2C Non:
(Financial))
• Influitive:
(Venture Round)
• Gig and Take:
$2000000 (Pre Seed)
• Telgea:
$3000000 (Series Unknown)
• HubiFi:
$3000000 (Seed)
• Fulcrum:
$18000000 (Series A)
• Fulcrum:
$19000000 (Series A)
• Fulcrum:
$3000000 (Seed)
• Frontdesk:
$13000000 (Series B)
• Frontdesk:
$7000000 (Series A)
• Wilya:
$2000000 (Pre Seed)
• Sweater:
$12000000 (Seed)
• New Era ADR:
$2000000 (Pre Seed)
• Sarna:
$950000 (Pre Seed)
• JOEZOO:
(Pre Seed)
• ProHabits:
$320000 (Pre Seed)
• Hallow:
(Pre Seed)
• Unsplash:
$10000000 (Series A)
• Schoola:
$4000000 (Series Unknown)
• Home Chef:
$5000000 (Series A)
• Home Chef:
$1000000 (Convertible Note)
• Recruiter.com:
$350000 (Angel)
• Cratejoy:
$6000000 (Series A)
• Preferral:
$530000 (Series Unknown)
• Influactive:
(Series Unknown)
• Crew:
$2000000 (Seed)
• Trace:
(Seed)
• Good&Co:
$1000000 (Seed)
• Popular Pays:
$200000 (Seed)
• GINKGOTREE:
$750000 (Series A)
• Glio:
(Seed)
• Faraday Bicycles:
(Seed)
• SocialCrunch:
(Seed)
• NoRedInk:
(Seed)
David Wieland
Toronto - Austin - Chicago - Midwest - Illinois, Canada, U.S.A.
Founder and Managing Partner at Motivate Venture Capital
Most Interested In
Solutions to problems that accelerating longevity will create.
Not Interested In
Adtech, med devices, pharma
David Wieland is a Co-Founder and serves as Co-Chairman & Investment Committee Member at IrishAngels. He is Co-Founder and Managing Director of Endowment Research Group. He is a member of the Investment Committee and is Chair of the firm's Venture Capital Investments. He is responsible for corporate strategy, capital raising, deal sourcing, and investment due diligence. He is Chairman of the Board at RIVS, a software company, and he is positioning the firm for an exit. Prior thereto, Wieland was CEO of Innflux and Powersurge Technologies, where he founded, grew, and sold both companies. He earned his B.A. from the University of Notre Dame and an MBA from the Northwestern University Kellogg School of Management. He also serves as Board Member at IrishAngels Ventures.
Seth Bannon serves as Co-Founding Partner at Fifty Years. Seth Bannon is the Chief Executive Officer & Co-Founder at Amicus. He is also an Angel investor. eth has invested in a range of startups shaping the world for the better -- from a company engineering microbes to produce industrial chemicals sustainably, to a company building small satellites to cover the earth in internet, to a company culturing meat to eat. Seth is also the co-founder of impact.tech, a community of entrepreneurs combining purpose with profit, and the founder & CEO of Amicus, a startup that builds digital organising tools for nonprofits and political campaigns. A graduate of Y Combinator, Seth was named twice to the Forbes 30 Under 30 list for Social Entrepreneurship.
How to connect with Angel Investors in the BioTech industry?
In the BioTech industry, angel investors such as Esther Dyson, Vinod Khosla, and Steve Jurvetson are prominent figures. These investors focus on startups offering innovative solutions in biotechnology, genomics, and medical research. Esther Dyson, an entrepreneur and investor, looks for biotech startups that have the potential to make significant advancements in healthcare and medicine. Vinod Khosla, founder of Khosla Ventures, invests in high-impact biotech companies with disruptive technologies. Steve Jurvetson, a co-founder of Future Ventures, seeks out startups that push the boundaries of biological science and innovation. To connect with these investors, attend biotech conferences, medical expos, and networking events such as BIO International Convention, JP Morgan Healthcare Conference, and SynBioBeta. Utilize platforms like AngelList and LinkedIn to identify and reach out to potential investors. When pitching, emphasize how your biotech solution addresses key challenges in healthcare and medical research, such as developing new therapies, improving diagnostic accuracy, or advancing genomic research. Highlight any traction you’ve gained, such as partnerships with research institutions, successful clinical trials, or regulatory approvals. Building relationships through initial informal meetings or discussions at industry panels can help establish trust with these investors. Demonstrating the impact of your technology through case studies or clinical results can also add credibility. Personalize your outreach by referencing the investor’s previous investments and explaining how your venture aligns with their interests. Demonstrating a sustainable business model with clear revenue streams, such as licensing, product sales, or research grants, will further strengthen your pitch. Leveraging endorsements or case studies from biotech experts can also enhance your credibility.
Case Studies: Successful Funding Rounds with Angel Investors on Angels Partners
Exotic Orange & Angels Partners: Turning Financial Simplicity Into Investment Success
